Reformulated Onsolis OK'd; Market Entry Not Until 2016
This article was originally published in Scrip
Executive Summary
There was some initial glee from investors on Aug. 13 on word the FDA had approved a reformulated version of BioDelivery Sciences International Onsolis (fentanyl buccal soluble film) CII as a therapy to manage breakthrough pain in patients with cancer who are opioid tolerant.